Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Abstract Text:

Enfuvirtide has been a cornerstone of salvage therapy for multidrug-resistant HIV. Raltegravir provides another novel class option, with the advantages of easier administration and improved tolerability. Thirty-five adults electively replaced enfuvirtide with raltegravir while the rest of their regimen was unchanged. All maintained virologic suppression after a median of 7 months except one who experienced a transiently detectable viral load after 5 months. The new regimen was well tolerated with no apparent new drug-related adverse clinical or laboratory events.

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: AIDS (London, England)

VOLUME: 22

Page Numbers: 1224-6

Journal Abbreviation: AIDS

ISSN: 1473-5571

DAY: 19

MONTH: Jun

YEAR: 2008

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8710219

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.

AFFILIATION: AIDS Research Programme, St Paul's Hospital, Providence Healthcare, Canada. mharris@cfenet.ubc.ca

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: AIDS

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen Related Publications

• A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
• A review of barriers and facilitators of HIV treatment among injection drug users.
• Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
• Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
• Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator related hemorrhagic transformation.
• Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
• Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells.
• Ethical and scientific issues surrounding solid organ transplantation in HIV-positive patients: Absence of evidence is not evidence of absence.
• Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage.
• Genetics of stroke: a review of recent advances.
• Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
• Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.
• Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption
• Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
• MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.
• Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006.
• Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases.
• NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells.
• Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
• Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.
• Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users.
• Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?
• Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
• The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.
• The use of highly active retroviral therapy to reduce HIV incidence at the population level.
• Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release.
• Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
• [Biological markers in spontaneous intracerebral hemorrhage]
• [Commentary] ANTIRETROVIRAL THERAPY: A KEY PART OF THE PUBLIC HEALTH RESPONSE TO INJECTION DRUG USE.
• [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.]